| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
1-Arachidoyl-sn-glycero-3-phosphocholine does not target a specific receptor but acts as a lysophospholipid that can interact with various cell surface receptors, including lysophosphatidic acid (LPA) receptors and G protein-coupled receptors (GPCRs) that recognize lysophosphatidylcholine (LysoPC). The compound can also be metabolized by enzymes such as phospholipase A2 (PLA2), lysophospholipase, and acyltransferases, which convert it to other lipid mediators. As a LysoPC species, 1-arachidoyl-sn-glycero-3-phosphocholine can modulate cell signaling, membrane fluidity, and lipid raft formation. The compound's effects are mediated through its incorporation into cell membranes, its release of lysophosphatidic acid (LPA) and other bioactive lipids, and its activation of intracellular signaling pathways. The saturated fatty acid chain (arachidoyl) contributes to the compound's physical properties, including its membrane interactions and its ability to form micelles and other lipid structures.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 1-arachidoyl-sn-glycero-3-phosphocholine can modulate cell signaling and lipid metabolism in various cell types. In macrophages and other immune cells, LysoPC species have been shown to activate inflammatory signaling pathways, including the NF-κB and MAPK pathways, leading to the production of pro-inflammatory cytokines. In endothelial cells, LysoPC can induce the expression of adhesion molecules and promote vascular inflammation. In cancer cells, LysoPC has been shown to promote cell proliferation and migration through the activation of GPCRs and the PI3K/AKT pathway. The specific effects of 1-arachidoyl-sn-glycero-3-phosphocholine depend on the cell type, the concentration, and the presence of other lipid mediators. The compound has also been used as a substrate in enzyme assays to measure the activity of PLA2, lysophospholipase, and other lipid-metabolizing enzymes. In cell-free systems, the compound is used as a standard for the identification and quantification of LysoPC species by LC-MS and other analytical methods.
|
| ln Vivo |
In vivo studies on 1-arachidoyl-sn-glycero-3-phosphocholine are limited, as the compound is primarily used as a research reagent rather than as a therapeutic agent. However, lysophospholipids are known to play important roles in various physiological and pathological processes, including inflammation, atherosclerosis, cancer, and neurodegenerative diseases. Elevated levels of LysoPC species have been associated with metabolic disorders and cardiovascular disease. The compound is used as a reference standard for the measurement of LysoPC levels in biological samples, enabling the study of lipid metabolism and the identification of disease biomarkers.
|
| Enzyme Assay |
For in vitro enzyme assays, 1-arachidoyl-sn-glycero-3-phosphocholine is used as a substrate for PLA2 and other phospholipases. The compound is dissolved in an appropriate solvent (e.g., ethanol or DMSO) and diluted in assay buffer containing calcium and other cofactors. The enzyme (e.g., PLA2 from snake venom, bee venom, or recombinant sources) is added to the reaction mixture, and the release of fatty acid (arachidic acid) and lysophospholipid is measured. The enzyme activity is quantified by measuring the fluorescence of a labeled substrate or by extracting the products and analyzing them by TLC, HPLC, or LC-MS. For lysophospholipase assays, the compound is used as a substrate, and the release of glycerol-3-phosphocholine and fatty acid is measured. For acyltransferase assays, the compound is used as an acceptor, and the incorporation of a fatty acyl-CoA is measured. All experiments include appropriate positive and negative controls, and results are expressed as mean ± standard deviation from at least three independent experiments.
|
| Cell Assay |
For in vitro cell-based assays, 1-arachidoyl-sn-glycero-3-phosphocholine is evaluated for its effects on cell signaling, proliferation, and inflammation in various cell types. Cells (e.g., macrophages, endothelial cells, cancer cells) are seeded in 6- or 12-well plates and treated with the compound at concentrations of 0.1-100 µM for 4-24 hours. Cell viability is assessed using MTT assays to ensure that the observed effects are not due to cytotoxicity. The production of inflammatory cytokines (TNF-α, IL-1β, IL-6) is measured by ELISA. The activation of signaling pathways (NF-κB, MAPK, PI3K/AKT) is assessed by Western blotting. Cell proliferation and migration are assessed using MTT and transwell assays, respectively. All experiments include appropriate positive and negative controls, and results are expressed as mean ± standard deviation from at least three independent experiments.
|
| Animal Protocol |
For in vivo animal experiments, 1-arachidoyl-sn-glycero-3-phosphocholine is not typically administered to animals as a therapeutic agent. However, the compound can be used as a reference standard in lipidomic studies. In a typical study, animals (e.g., mice, rats) are fed a specific diet or treated with a drug, and blood and tissue samples are collected. Lipids are extracted from the samples using Folch or Bligh-Dyer extraction, and the LysoPC species are analyzed by LC-MS/MS using 1-arachidoyl-sn-glycero-3-phosphocholine as an internal standard or as a reference for quantification. The levels of LysoPC species are correlated with disease states, drug effects, or metabolic changes. All animal procedures are conducted in accordance with institutional guidelines for the care and use of laboratory animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1-arachidoyl-sn-glycero-3-phosphocholine are not applicable, as the compound is a lipid that is naturally present in the body and is not used as a therapeutic agent. The compound has a molecular weight of 551.74 g/mol and a molecular formula of C₂₈H₅₈NO₇P. It is soluble in organic solvents such as chloroform, methanol, and DMSO, and it can be dispersed in aqueous solutions with the aid of detergents or sonication. The compound should be stored as a powder at -20°C, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
1-Arachidoyl-sn-glycero-3-phosphocholine is generally considered to be non-toxic at the concentrations used in research applications. The compound is a naturally occurring lysophospholipid that is a normal component of cell membranes and lipoproteins. However, as with all chemicals, appropriate safety precautions should be taken when handling the compound, including the use of personal protective equipment and working in a well-ventilated area. The compound is for research use only and is not intended for human therapeutic use.
|
| Additional Infomation |
1-Eicosanoyl-sn-glycerol-3-phosphate choline is a 1-O-acyl-sn-glycerol-3-phosphate choline, wherein the acyl group is definitively defined as eicosanoyl. It is a 1-O-acyl-sn-glycerol-3-phosphate choline, and also a lysophosphatidylcholine 20:0. Functionally, it is related to eicosanoic acid. 1-Eicosanoyl-sn-glycerol-3-phosphate choline has been reported in the cotton aphid (Lysiphlebia japonica) and the cotton aphid (Aphis gossypii), and relevant data are available.
1-Arachidoyl-sn-glycero-3-phosphocholine is a research-use only compound and has not been approved for clinical applications by any regulatory authority. It is a lysophospholipid (LyP) that consists of a glycerol backbone with an arachidoyl (C20:0) fatty acid chain at the sn-1 position and a phosphocholine head group at the sn-3 position. The compound has a molecular formula of C₂₈H₅₈NO₇P and a molecular weight of 551.74 g/mol. 1-Arachidoyl-sn-glycero-3-phosphocholine is used in research on lipid metabolism, cell signaling, and the role of lysophospholipids in health and disease. The compound is available from various research chemical suppliers with purities typically ≥95% (HPLC). Storage recommendations include keeping the compound in a tightly sealed container, protected from light and moisture, at -20°C. |
| Molecular Formula |
C28H58NO7P
|
|---|---|
| Molecular Weight |
551.736390590668
|
| Exact Mass |
551.395
|
| CAS # |
108341-80-6
|
| Related CAS # |
1-Arachidoyl-sn-glycero-3-phosphocholine-d4;2483831-16-7
|
| PubChem CID |
24779473
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.21
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
37
|
| Complexity |
575
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
|
| InChi Key |
UATOAILWGVYRQS-HHHXNRCGSA-N
|
| InChi Code |
InChI=1S/C28H58NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h27,30H,5-26H2,1-4H3/t27-/m1/s1
|
| Chemical Name |
[(2R)-2-hydroxy-3-icosanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8124 mL | 9.0622 mL | 18.1245 mL | |
| 5 mM | 0.3625 mL | 1.8124 mL | 3.6249 mL | |
| 10 mM | 0.1812 mL | 0.9062 mL | 1.8124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
